" class="no-js "lang="en-US"> Dr. Colin Hayward - Medtech Alert
Wednesday, December 04, 2024

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Dr. Colin Hayward | PTF

Dr. Colin Hayward

About Dr. Colin Hayward

Chief Medical Officer Biotech / Oncology / CRO

Related Story

Diseases

 Telix Pharmaceuticals ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU | PTF

Telix Pharmaceuticals ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU Along with Theranostic Pipeline Advances

December 22 2022

Telix Pharmaceuticals has announced that the completed pivotal Phase III ZIRCON study of TLX250-CDx in […]

Clinical Trials

 First Patient Dosed in Phase II 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy | PTF

First Patient Dosed in Phase II 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy

November 22 2022

Telix Pharmaceuticals has announced that a first patient has been dosed in a Phase II […]